Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 2
1993 2
1994 4
1995 4
1996 6
1997 1
1998 6
1999 5
2000 4
2001 4
2002 7
2003 10
2004 6
2005 16
2006 10
2007 16
2008 9
2009 11
2010 13
2011 7
2012 7
2013 11
2014 10
2015 3
2016 9
2017 9
2018 9
2019 5
2020 19
2021 14
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

222 results
Results by year
Filters applied: . Clear all
Page 1
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M. Guignabert C, et al. Among authors: molimard m. J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2. J Clin Invest. 2016. PMID: 27482885 Free PMC article. Clinical Trial.
Prévention des risques liés à un usage inapproprié/consommation inutile des médicaments.
Cracowski JL, Muller S, Anglade I, Bonnefond G, Bouhanick B, Bouquet S, Cabut S, Daynès P, Denis B, Durand D, Jonville-Béra AP, Lahouegue A, Léo M, Micallef J, Molimard M, Penfornis C, Querol-Ferrer V. Cracowski JL, et al. Among authors: molimard m. Therapie. 2022 Jan-Feb;77(1):69-78. doi: 10.1016/j.therap.2021.12.020. Epub 2022 Jan 4. Therapie. 2022. PMID: 35067334 French. No abstract available.
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Marin D, et al. Among authors: molimard m. J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385986 Free PMC article.
Information et communication sur les risques liés au médicament et son bon usage auprès des professionnels de santé et du public : principe de précaution, gestion du risque, communication pendant et en dehors des situations de crise.
Molimard M, Bernaud C, Lechat P; et les participants à la table ronde N°6 de Giens XXIX :, Bejan-Angoulvant T, Benattia C, Benkritly A, Braunstein D, Cabut S, David N, Fourrier-Réglat A, Gallet B, Gersberg M, Goni S, Jolliet P, Lamarque-Garnier V, Le Jeunne C, Leurs I, Liard F, Malbezin M, Micallef J, Nguon M. Molimard M, et al. Therapie. 2014 Jul-Aug;69(4):355-60. doi: 10.2515/therapie/2014044. Therapie. 2014. PMID: 27393228 French. No abstract available.
[Therapeutic education, compliance and self-medication].
Rosellini P, Berdaï D, Molimard M, Girodet PO. Rosellini P, et al. Among authors: molimard m. Rev Prat. 2020 Jun;70(6):e191-e197. Rev Prat. 2020. PMID: 33058624 French. No abstract available.
Pharmacokinetics in special populations.
Poggesi I, Benedetti MS, Whomsley R, Le Lamer S, Molimard M, Watelet JB. Poggesi I, et al. Among authors: molimard m. Drug Metab Rev. 2009;41(3):422-54. doi: 10.1080/10837450902891527. Drug Metab Rev. 2009. PMID: 19601721 Review.
222 results